Effects of long-term remote ischemic preconditioning on exercise performance in athletes: a systematic review and meta-analysis

YIWEI LIANG1, MENGYUN FENG2, RUOLAN YANG3, JIAYI GOU3, MENGYU WANG3, JINZHEN ZHAO3, XIANQI PAN3, JIAN LI3,4, QI HAN5

1China Volleyball College, Beijing Sport University, Beijing, China; 2Shanghai Pudong New Area Qunfeng Senior High School, Shanghai, China; 3The Sports Coaching College, Beijing Sport University, Beijing, China; 4Key Laboratory of Sport Training of General Administration of Sport of China, Beijing, China; 5Sports Nutrition Center, National Institute of Sports Medicine, Beijing, China.

Summary. Background. Due to its ease of operation, non-invasive nature, and low cost, ischemic preconditioning (IPC) has been widely adopted in sports as an auxiliary tool for enhancing athletic performance. This study performed a systematic review and meta-analysis of randomized controlled trials to evaluate the effects of long-term IPC on athletes’ performance. Method. The meta-analysis was conducted in accordance with the PRISMA guidelines, and figures were generated using Review Manager 5.4 software. Relevant keywords such as “ischemic preconditioning”, “remote ischemic preconditioning”, “exercise performance”, and “athlete”, were used to search the CNKI, Wanfang Data, VIP, PubMed, Embase, Web of Science, and Cochrane Library databases. The search included both Chinese and English language literature from database inception to April 18, 2026. Primary outcomes were sports performance (completion time, CT), aerobic endurance (peak oxygen uptake, VO₂ peak), and anaerobic power output (mean power output, MPO; peak power output, PPO; fatigue index, FI%). Secondary outcomes included metabolic stress (blood lactate, BLa), muscle damage and inflammatory markers (creatine kinase, CK; C-reactive protein, CRP; white blood cell count, WBC), cardiovascular responses (systolic blood pressure, SBP; diastolic blood pressure, DBP; heart rate, HR), rating of perceived exertion (RPE), and erythrocyte system parameters (red blood cell count, RBC; hemoglobin, Hb; red blood cell distribution width, RDW). Effect sizes were pooled using standardized mean difference (SMD) or mean difference (MD), with random or fixed-effects models applied depending on heterogeneity. Results. Eleven studies involving 209 athletes were included. Compared with controls, a statistically significant increase in PPO was observed in a limited number of studies (MD = 97.38 W, 95% CI: 22.33 to 172.44, p < 0.05), along with significant changes in WBC (MD = 0.94 ×10⁹/L, 95% CI: 0.10 to 1.79, p < 0.05), and RDW (MD = 0.54%, 95% CI: 0.20 to 0.97, p < 0.05). No significant differences were found in CT, VO₂ peak, MPO, FI%, BLa, CK, CRP, SBP, DBP, HR, RPE, RBC, or Hb (all p > 0.05). Conclusion. The PPO finding should be interpreted with caution, as it was not consistently supported by other anaerobic indicators (MPO, FI%) and sensitivity analysis suggested influence from individual studies. Current evidence does not support long-term IPC as an effective intervention for enhancing overall athletic performance, accelerating recovery from muscle damage, or reducing perceived fatigue in athletes.

Key words. Ischemic preconditioning, IPC, athlete, athletic performance, meta-analysis.

Effetti del pre-condizionamento ischemico remoto a lungo termine sulle prestazioni fisiche negli atleti: una revisione sistematica e una metanalisi

Riassunto. Background. Background. Economico, non invasivo e di facile esecuzione, il pre-condizionamento ischemico (IPC) è ampiamente adottato nello sport. Questa revisione sistematica e metanalisi di RCT valuta gli effetti dell’IPC a lungo termine sulle prestazioni degli atleti. Metodo. Condotta secondo le linee guida PRISMA, la ricerca ha incluso la letteratura in cinese e inglese (fino al 18 aprile 2026) da principali database (PubMed, Embase, Web of Science, Cochrane, CNKI, Wanfang, VIP) con parole chiave pertinenti. Esiti primari: prestazione (CT), resistenza aerobica (VO₂ max) e potenza anaerobica (MPO, PPO, FI%). Esiti secondari: stress metabolico (BLa), danno muscolare/infiammazione (CK, CRP, WBC), risposte cardiovascolari (SBP, DBP, HR), sforzo percepito (RPE) e parametri eritrocitari (RBC, Hb, RDW). Le dimensioni dell’effetto sono state aggregate tramite SMD o MD (modelli a effetti fissi o casuali in base all’eterogeneità). Risultati. Inclusi 11 studi (209 atleti). Rispetto ai controlli, in un numero limitato di studi si è osservato un aumento significativo della PPO (MD = 97,38 W, IC 95%: 22,33-172,44, p < 0,05), della conta leucocitaria (MD = 0,94 × 10⁹/L, IC 95%: 0,10-1,79, p < 0,05) e dell’RDW (MD = 0,54%, IC 95%: 0,20-0,97, p < 0,05). Nessuna differenza significativa per CT, VO₂ picco, MPO, FI%, BLa, CK, CRP, SBP, DBP, HR, RPE, RBC o Hb (tutte p > 0,05). Conclusione. Il risultato sulla PPO va interpretato con cautela, poiché non supportato da altri indicatori anaerobici (MPO, FI%) e sensibile all’analisi di sensibilità.

Parole chiave. Pre-condizionamento ischemico, IPC, atleta, prestazioni atletiche, metanalisi.

Introduction

The essence of competitive sports lies in embodying the Olympic spirit of “Faster, Higher, Stronger-Together”. With the continuous advancement of exercise science, the demands on athletes’ performance have increased significantly in recent years, accompanied by growing intensity in international competition. Currently, traditional training methods are becoming less effective in enhancing athletic performance. Coaches are urgently seeking alternative training strategies to help athletes achieve new breakthroughs1.

Ischemic preconditioning (IPC) was first identified in 1986 by Murry et al.2. This technique induces endogenous protective mechanisms in tissues and organs by applying brief, intermittent cycles of ischemia and reperfusion to specific regions3,4. The most widely used protocol involves three to four cycles of 5-minute ischemia followed by 5-minute reperfusion5,6. IPC has been extensively applied in clinical practice7 due to its ease of implementation, non-invasive nature, and low cost. It also has a favorable safety profile and a low risk of adverse events. Consequently, IPC has been increasingly adopted by researchers as an adjunct intervention to enhance athletic performance.

Most existing studies have focused on the acute effects of a single session of IPC on athletic performance8. Acute IPC only triggers transient hemodynamic and neural effects9. In contrast, long-term IPC can induce more durable improvements in exercise performance through cumulative physiological adaptations, including upregulation of antioxidant enzymes, enhanced mitochondrial biogenesis, and sustained activation of anti-inflammatory pathways10. Long-term IPC may confer additional benefits through anti-remodeling effects11,12. It can reduce plasma calprotectin levels and total white blood cell count11, improve endothelial function via signal transducer and activator of transcription 3 (STAT-3) activation13, and lower blood pressure and N-terminal pro-brain natriuretic peptide (NT-proBNP) levels14. Therefore, it is necessary to distinguish between acute and long-term IPC when evaluating their effects on athletes.

Despite the potential benefits, the long-term impact of IPC on athletes’ performance remains controversial. Athletic performance is not a single concept15,16 but encompasses multiple dimensions, such as aerobic endurance and anaerobic power, each involving different energy metabolism systems and physiological mechanisms. Currently, no studies systematically evaluate the specific effects of long-term IPC on these different performance dimensions.

This study employed a meta-analysis to synthesize findings from domestic and international research on long-term IPC in athletes. Data were collected on specific performance indicators (completion time, CT; aerobic endurance; anaerobic power output; and rating of perceived exertion, RPE) and blood biomarkers (metabolic stress, muscle damage and inflammatory markers, cardiovascular responses, and erythrocyte system parameters). These data were then quantitatively analyzed using statistical methods to evaluate the efficacy of this intervention, resolve existing discrepancies, and enhance the reliability of the conclusions.

Materials and methods

Study and registration

This systematic review and meta-analysis were registered with PROSPERO (CRD420251135453) and conducted in accordance with the PRISMA guidelines. The methods of this review were strictly adhered to the pre-registered protocol. No amendments were made.

Eligibility criteria

Inclusion criteria

The inclusion criteria for this analysis were defined according to the PICOS framework, as follows: (1) Population (P): healthy adult athletes over 18 years of age, with no significant differences in baseline characteristics between groups. (2) Intervention (I): the experimental group received repeated IPC interventions for a period of no less than 7 days17-19. This threshold is operational in nature, adopted primarily to distinguish long-term repeated IPC protocols from single-session acute IPC interventions. Due to the absence of dose-response studies examining optimal intervention duration in the current literature, this cutoff is not grounded in rigorous physiological evidence. (3) Comparison (C): randomized controlled trials comparing an IPC intervention group with a sham or no-intervention control group. (4) Outcomes (O): performance indicators (e.g., CT, aerobic endurance, anaerobic power output, RPE) and blood biomarkers (e.g., metabolic stress, muscle damage, inflammation, cardiovascular responses, erythrocyte parameters), with data extractable as sample size, mean, and SD. (5) IPC application site: proximal thighs (unilateral or bilateral). (6) No restrictions regarding the intensity or duration of IPC interventions.

Exclusion Criteria

(1) Duplicate publications; (2) publications with copyright restrictions or unavailable full text; (3) studies with non-rigorous experimental designs or inappropriate statistical methods; (4) papers with incomplete or irretrievable outcome data.

Literature search strategy

To identify eligible studies, comprehensive literature searches were performed across both Chinese and English databases, including China National Knowledge Infrastructure (CNKI), Wan Fang Data, China Science and Technology Journal Database (VIP Database), PubMed, Embase, Web of Science, and the Cochrane Library. The search period extended from the inception of each database to April 18, 2026. No restrictions were applied regarding region, publication type or language.

Synonyms were combined using the Boolean operator “OR”, and the search strategy was constructed as follows: ([ischemic preconditioning] OR [IPC] OR [remote ischemic conditioning] OR [remote conditioning] OR [transient limb ischemia] OR [muscle ischemia]) AND ([exercise] OR [sports] OR [sports performance] OR [aerobic] OR [aerobic capacity] OR [anaerobic capacity] OR [anaerobic] OR [strength] OR [power]) AND ([athlete] OR [player]).

Study selection and data extraction

Literature retrieved from the databases was initially screened against the inclusion criteria. Duplicate records were first removed using Zotero software. After deduplication, an initial screening was performed based on the titles, abstracts, and keywords of the retrieved records. Studies that did not meet the criteria were excluded. The remaining articles underwent a second screening by a third researcher, which involved full-text assessment to determine final eligibility. Studies not satisfying the inclusion criteria were systematically excluded.

Data extraction was carried out independently by two researchers. Any discrepancies were resolved through discussion or by consultation with a third researcher. The following information was extracted from each eligible study: (1) first author’s name and year of publication; (2) sample size and age of participants; (3) intervention protocols (including frequency and duration) for both experimental and control groups; (4) outcome indicators; (5) main conclusions.

Risk of bias in studies

The risk of bias was assessed by two independent reviewers using the Cochrane Risk of Bias Tool version 2 (RoB2). Each study was evaluated across five domains: bias arising from the randomization process, bias due to deviations from intended interventions, bias due to missing outcome data, bias in measurement of the outcome, and bias in selection of the reported result. Based on the content of the articles, responses of “Y”, “PY”, “PN”, “N”, or “NI” were selected for each domain-specific question, ultimately generating a final judgment of “Low risk,” “High risk,” or “Some concerns” for each domain. The RoB2 Discrepancy check function was used for cross-verification between the two reviewers, and the SPSS software was employed to conduct a kappa test for assessing inter-rater reliability. Any disagreements were resolved through discussion or by consulting a third reviewer.

Meta-analysis

The meta-analysis was conducted independently by two authors. Basic characteristics of the participants were extracted in the form of mean, standard deviation, and sample size. The meta-analysis used data representing the changes from baseline to post-intervention (mean differences). Data were processed and forest plots were generated using Review Manager 5.4 software. The mean difference (MD) was used when all studies measured the outcome with the identical scale or unit; otherwise, the standardized mean difference (SMD) was used to harmonize results from different instruments.

When I² ≥ 50% or p ≤ 0.1, significant heterogeneity was considered present, and a random-effects model was applied. Subgroup analysis and sensitivity analysis were conducted to explore potential sources of heterogeneity. Forest plots were used to compare effects between the intervention and control groups. A p-value < 0.05 was considered statistically significant. Publication bias was assessed using funnel plots.

Results

Study selection

A total of 1803 relevant records were retrieved from the databases using the predefined search strategy. All records were imported into the reference management software Zotero. After removing duplicates and conducting multiple rounds of screening, 11 articles that met the eligibility criteria were ultimately included in the study. Most studies on athletes and IPC were excluded due to being non-long-term studies20-22. Figure 1 shows the literature screening process.




Study characteristics

A total of 11 studies that met the inclusion criteria were included, involving 209 athletes. Among them, 125 participants were assigned to the experimental group and 116 to the control group, with some athletes taking part in both groups following a washout period.

Table 1 presents the characteristics of all the included studies. The experimental group received IPC intervention, whereas the control group received placebo intervention or no specific intervention.










To assess the impact of the intervention on athletic performance, the following outcome categories were used: primary outcomes included Sports performance, Aerobic endurance performance, and Anaerobic power output; secondary outcomes included Metabolic stress, Muscle damage and inflammatory markers, Cardiovascular responses, Rating of Perceived Exertion (RPE), and Erythrocyte system.

Risk of bias in studies

The kappa coefficient between the two reviewers was 0.801, P < 0.001, indicating a good level of agreement. Figure 2 shows the risk of bias assessment graph, and Figure 3 presents the overall summary of the risk of bias.







Of the studies assessed, 45.5% were judged as “Low risk” and 54.5% as having “Some concerns” in the domain of bias arising from the randomization process, with none rated as “High risk.” Regarding bias due to deviations from intended interventions, 72.7% were rated “Low risk,” 27.3% raised “Some concerns,” and none were considered “High risk.” For bias due to missing outcome data and measurement of the outcome, all studies (100%) were judged “Low risk,” with no studies rated “High risk” or “Some concerns.” Finally, for bias in the selection of the reported result, 36.4% were deemed “Low risk” and 63.6% prompted “Some concerns”; none were classified as “High risk.”

Meta-analysis

Sports performance

Six studies reported CT. Studies were stratified by exercise modality: running23-26 and swimming25,27. Due to differences in running distances across studies, the effect sizes were pooled using SMD.

As shown in the forest plot (figure 4), for the running subgroup, moderate heterogeneity was observed (I² = 64%, p < 0.05), and thus a random-effect model was applied. Meta-analysis results showed SMD = -0.17 (95% CI: -0.87, 0.53; p > 0.05).




For the swimming subgroup, no heterogeneity was detected (I² = 0%, p > 0.05), and SMD = 0.00 (95% CI: -0.48, 0.48; p > 0.05). The pooled analysis of the two subgroups yielded SMD = –0.10 (95% CI: –0.52 to 0.32; p = 0.64), indicating that IPC had no statistically significant effect on action completion time compared with the control group.

Aerobic Endurance Performance

Three studies23, 26, 28 reported the effects of IPC on aerobic endurance performance, including peak oxygen uptake (VO₂ peak). The units used in the three studies were consistent (mL·min⁻¹·kg⁻¹), so the MD was used for effect size analysis. As shown in figure 5, moderate heterogeneity was observed (I² = 51%, p > 0.05), and a random-effect model was applied. The meta-analysis results showed MD = 0.11 (95% CI: –3.70, 3.93; p > 0.05), indicating that the difference in effects between IPC and placebo was not statistically significant.




Anaerobic Power Output

1. Mean power output (MPO)

Four studies27-30 reported the effects of IPC on MPO. Although the units used in the four studies were consistent, the numerical values varied considerably across studies, so the SMD was used for effect size analysis. As shown in figure 6, moderate heterogeneity was observed (I² = 54%, p > 0.05), and a random-effects model was applied.




The meta-analysis results showed SMD = 0.50 (95% CI: –0.26, 1.26; p > 0.05), indicating that there was no statistically significant difference in MPO between ischemic preconditioning and placebo conditions in athletes.

1. Peak power output (PPO)

Four studies27-30 reported the effects of IPC on PPO. The units were consistent across the four studies (W), so the MD was used for effect size analysis. As shown in figure 7 (I² = 31%, p > 0.05), a fixed-effect model was applied.




The meta-analysis results showed MD = 97.38 (95% CI: 22.33, 172.44; p < 0.05), indicating that there was a statistically significant difference in PPO between the ischemic preconditioning and control groups in athletes.

2. Fatigue index (FI%)

Three studies27-29 reported the effects of IPC on athletes’ FI%. The methods for calculating the fatigue index may have differed across studies; therefore, the SMD was used. As shown in figure 8 (I² = 0%, p > 0.05), a fixed-effect model was applied.




The meta-analysis results showed SMD = –0.24 (95% CI: –0.80, 0.32; p > 0.05), indicating that there was no statistically significant difference in the effect on athletes’ FI% between the ischemic preconditioning and control groups.

Metabolic Stress

Four studies24,27,30,31 reported the effects of IPC on metabolic stress in athletes, including blood lactate (BLa). Different exercise protocols were used across studies, so the SMD was adopted. As shown in figure 9, moderate heterogeneity was observed (I² = 63%, p = 0.05), and a random-effects model was applied. The meta-analysis results showed that there was no statistically significant difference between the IPC and control groups in BLa (SMD = 0.38; 95% CI: –0.37, 1.12; p > 0.05).




Muscle Damage and Inflammatory Marker

1. Creatine kinase (CK)

Two studies24,32 reported the effects of IPC on CK. The data values varied considerably across studies; therefore, the SMD was used. As shown in figure 10, moderate heterogeneity was observed I² = 59% (p > 0.05), and a random-effects model was applied.




The meta-analysis results showed SMD = –0.73 (95% CI: –1.72, 0.25; p > 0.05), indicating that there was no statistically significant difference in CK between IPC and placebo conditions.

2. C-reactive protein (CRP)

Two studies24,32 reported the effects of IPC on CRP. The testing methods used in the included studies may have differed, so SMD was adopted. As shown in figure 11, high heterogeneity was observed (I² = 74%, p = 0.05), and a random-effects model was applied. The meta-analysis results showed SMD = –0.64 (95% CI: –1.82, 0.64; p > 0.05), indicating that there was no statistically significant difference in CRP between the IPC and control groups in athletes.




3. White blood cell count (WBC)

Two studies24,28 reported the effects of IPC on WBC. The units used in the included studies were consistent (×10⁹/L), so the MD was adopted. As shown in figure 12, I² = 0%, p > 0.05, and a fixed-effect model was applied. The meta-analysis results showed MD = 0.94 (95% CI: 0.10, 1.79; p < 0.05), indicating that the difference in WBC between IPC and placebo conditions was statistically significant.




Cardiovascular Responses

1. Blood pressure

Four studies23,25,30,33 reported the effects of IPC on blood pressure, including systolic blood pressure (SBP) and diastolic blood pressure (DBP). As shown in figure 13, for DBP, I² = 71% (p < 0.05), indicating high heterogeneity, and a randomeffects model was applied. The meta-analysis results showed that there was no statistically significant difference between the two groups in SBP (SMD = –0.15; 95% CI: –0.60, 0.30; p > 0.05) or DBP (SMD = –0.11; 95% CI: –0.88, 0.66; p > 0.05).




2. Heart rate

Three studies25, 30, 33 reported the effects of IPC on resting heart rate (HR rest), and six studies23,24,27,28,30,31 reported on maximal heart rate (HRmax). As shown in figure 14, I² = 0% (p > 0.05), and a fixed-effect model was applied.




The meta-analysis results showed that there was no statistically significant difference between the two groups in HR rest (SMD = 0.01; 95% CI: –0.40, 0.42; p > 0.05) or HRmax (SMD = 0.22; 95% CI: –0.14, 0.59; p > 0.05).

RPE

Four studies25, 27, 30, 31 reported the effects of IPC on RPE. As shown in figure 15, I² = 43% (p > 0.05), and a randomeffects model was applied.




The meta-analysis results showed SMD = 0.05 (95% CI: –0.49, 0.60; p > 0.05), indicating that there was no statistically significant difference in RPE between IPC and placebo conditions in athletes.

Erythrocyte System

1. Red blood cell count (RBC)

Three studies24,28,32 reported the effects of IPC on RBC. As shown in figure 16, I² = 0% (p > 0.05), and the units were consistent (×10¹²/L).




A fixed-effect model using the MD was applied. MD = –0.02 (95% CI: –0.17, 0.12; p > 0.05), indicating that there was no statistically significant difference in RBC between the IPC and control groups in athletes.

2. Hemoglobin concentration (Hb)

Four studies23, 24, 28, 32 reported the effects of IPC on Hb. The units were consistent across the included studies (g/dL), so the MD was used. As shown in figure 17, I² = 75% (p < 0.05), indicating high heterogeneity, and a randomeffects model was applied. The meta-analysis results showed MD = 0.11 (95% CI: –0.59, 0.82; p > 0.05), indicating that the difference in Hb between the two groups was not statistically significant.




3. Red blood cell distribution width (RDW)

Two studies24,28 reported the effects of IPC on RDW. As shown in figure 18, I² = 9% (p > 0.05), and the units of RDW were consistent across the included studies (%). A fixedeffect model using the MD was applied.




The meta-analysis results showed that the difference between IPC and placebo in RDW was statistically significant (MD = 0.54; 95% CI: 0.20, 0.97; p < 0.05).

Sensitivity analysis

Sensitivity analysis performed using Review Manager 5.4 by sequentially excluding each included study indicated that the pooled results for most outcome measures were robust, with no substantial change in the direction or significance of the effect estimates (table 2). The exceptions were VO₂ peak, MPO, PPO, BLa, DBP, and Hb levels, for which the results were less stable.







Sensitivity analysis indicated that the pooled results for most outcome measures were robust. However, it should be noted that due to the limited number of studies included for each outcome (mostly 2-4 studies), the capacity of sensitivity analysis to detect sources of heterogeneity is inherently constrained. Therefore, the observed heterogeneity across outcomes should be fully considered when interpreting the results.

Publication bias

According to the recommended threshold for funnel plot analysis (≥10 included studies), a funnel plot was generated only for HR (figure 19), which included nine studies.




The funnel plot showed a roughly symmetric distribution around the pooled effect estimate, suggesting a low risk of publication bias. For the remaining outcome measures, the number of included studies was insufficient (<10) to perform meaningful funnel plot analysis. Therefore, publication bias cannot be excluded for these outcomes, and the results should be interpreted with caution.

Discussion

Potential Mechanisms of IPC in Improving Exercise Performance

IPC applies brief cycles of ischemia-reperfusion to a limb2, triggering endogenous protective mechanisms through local mediators such as adenosine, 34, 35 bradykinin36, and opioid peptides37, which activate multiple signaling pathways38,39.

Early preconditioning is receptor-mediated40, involving translocation and activation of protein kinase C isoforms41, whereas late preconditioning may attenuate inflammatory responses through NF-κB-mediated upregulation of IκB and subsequent iNOS transcription42.

Based on these established mechanisms, it has been hypothesized that repeated IPC may confer sustained benefits to athletic performance through cumulative physiological adaptations, including upregulation of antioxidant enzymes, enhanced mitochondrial biogenesis, activation of anti-inflammatory pathways, and improved endothelial function10. However, these mechanistic pathways have been primarily characterized in cardiac and clinical contexts, and their direct relevance to exercise performance in athletes remains to be established.

Safety and Feasibility of IPC in Exercise Training

IPC has been widely used in clinical and surgical settings and is generally well tolerated43-45, with transient cuff-related discomfort being the only commonly reported side effect46. This safety profile supports the feasibility of incorporating IPC into exercise training protocols. Nevertheless, the translation of IPC from clinical populations to healthy athletic cohorts requires separate evaluation, as the physiological baseline and adaptive capacity of athletes differ substantially from patient populations

Meta-Analysis Results

This meta-analysis primarily focused on the effects of long-term (≥7 days) IPC on athletic performance and physiological parameters in athletes. Unlike acute IPC, long-term IPC has been hypothesized to confer more sustained benefits to athletic performance through cumulative physiological adaptations, including upregulation of antioxidant enzymes, enhancement of mitochondrial biogenesis, sustained activation of anti-inflammatory pathways, and improvement of endothelial function10.

In addition, long-term IPC intervention may offer additional benefits through anti-remodeling mechanisms11,12, thereby reducing calprotectin and total white blood cell count and exerting mild anti-inflammatory and anti-remodeling effects.11 Long-term regular IPC can also improve endothelial function in patients with coronary artery disease, possibly through STAT-3 activation and increased endothelial progenitor cells13, while enhancing skeletal muscle function, lowering blood pressure, and reducing NT-proBNP levels14; Previous studies have shown that repeated IPC for 10 days downregulates pro-inflammatory gene expression in circulating leukocytes and alters neutrophil function17; one week of IPC treatment improves coronary microcirculation18; and seven consecutive days of IPC improves local and systemic endothelial function and microcirculation in healthy individuals, with effects persisting after the intervention19.

Based on the above evidence, we defined an intervention duration of ≥7 days as long-term IPC to distinguish it from previous studies on acute or short-term IPC effects. Candidly, this threshold was chosen primarily for operational feasibility rather than being grounded in a physiologically established dose-response relationship. Although existing evidence suggests that 7-day IPC can induce certain biological changes, these studies were conducted predominantly in clinical populations and did not systematically compare different intervention durations. Therefore, this definition should be understood as a classification tool for research purposes rather than a biological boundary.

This meta-analysis included 11 randomized controlled trials with a total of 209 athletes. All athletes received long-term (≥7 days) IPC intervention via proximal femoral artery occlusion. The meta-analysis results showed that, compared with the control group, the IPC group had significant improvements in PPO, WBC, and RDW (p < 0.05). No significant differences were found in CT, VO₂ peak, MPO, FI%, BLa, CK, CRP, SBP, DBP, HR, RPE, RBC, or Hb (p > 0.05).

(1) Exercise performance: IPC had no significant effect on CT (p > 0.05). The running subgroup showed moderate heterogeneity (I² = 64%), while the swimming subgroup showed no heterogeneity (I² = 0%). Long-term IPC failed to shorten the time to complete a fixed task in athletes. This finding is inconsistent with the “prolonged time to exhaustion” observed in some acute IPC studies.47 Several factors may explain this discrepancy. Athletes’ daily training may have already optimized exercise economy and metabolic efficiency, leaving limited additional benefit from long-term IPC. In addition, differences in running distance and intensity across studies may affect IPC sensitivity. The high heterogeneity in the running subgroup mainly originated from differences in test distance. Brzezińska et al. used a 400-m short-distance run24, which primarily reflects anaerobic glycolytic capacity. Loukas et al.23 and Slysz26 used approximately 1-km repeated runs and a 1-km time trial, respectively, representing mixed energy supply. Sari and Özkaya25 used a predominantly aerobic metabolism test. Although SMD was used to unify effect sizes, the impact of different distances could not be completely eliminated.

(2) Aerobic endurance: IPC had no significant effect on VO₂ peak (p > 0.05), with moderate heterogeneity (I² = 51%). VO₂ peak is a core physiological indicator of aerobic endurance, reflecting the upper limit of oxygen utilization by the cardiopulmonary system and muscle tissue.48 Theoretically, long-term IPC may improve flow-mediated dilation via upregulation of endothelial nitric oxide synthase (eNOS),19 and promote mitochondrial biogenesis.49 However, the lack of improvement in VO₂ peak may reflect insufficient intervention duration to induce central adaptations in the included studies. Heterogeneity may have arisen from differences in IPC pressure (250 mmHg, 220 mmHg, individualized LOP) and differences in control conditions.

(3) Anaerobic power output: only PPO was significantly better than the control group (p < 0.05), whereas MPO and FI% showed no significant improvement (p> 0.05). PPO represents short-term maximal force-generating capacity, relying on the phosphagen system and neuromuscular function. The improvement in PPO could be partly explained by mechanisms such as inducing skeletal muscle mitochondrial biogenesis to enhance ATP regeneration efficiency49, enhancing motor unit recruitment and neuromuscular conduction50, improving microcirculation and oxygen extraction capacity19, and activating the STAT-3 pathway to increase endothelial progenitor cells and improve muscle perfusion13. The pooled heterogeneity was low (I² = 31%). Sensitivity analysis showed that, except for study 4, excluding any other study did not change the significance of the effect size, indicating that the overall result was relatively robust. The discrepancy with MPO, which also reflects anaerobic capacity, may be because peak power relies more on instantaneous energy release and neural drive, whereas mean power is more influenced by endurance factors. This finding is consistent with the conclusions of Wu et al.51. but inconsistent with Carvalho and Barroso52, who observed in an acute study that IPC improved strength endurance performance during high-intensity resistance training.

(4) Metabolic stress, muscle damage, and inflammation: BLa, CK, and CRP showed no significant changes (p > 0.05), but WBC was significantly increased (p < 0.05). This may be related to altered neutrophil function as proposed by Shimizu et al.17. However, regarding the promotion of exercise recovery, the results of this study are inconsistent with those of Maia et al.53 The heterogeneity in CK and CRP mainly originated from large differences in baseline levels across the included studies. The Brzezińska group had a high baseline CK (281.69 U/L) and CRP of 0.88 mg/L, whereas the Mieszkowski group had normal CK (107.70 U/L) and mildly elevated CRP (2.92 mg/L).

Interpretation of the observed WBC changes requires caution, as levels are influenced by hydration status, circadian rhythm, and other factors54. The statistical significance detected in this meta-analysis should not be overinterpreted as evidence of enhanced immunity or accelerated recovery.

Endurance-trained elite athletes exhibit lower WBC, neutrophil, and monocyte counts than athletes in other disciplines, likely reflecting an aerobic training-induced inflammatory adaptation55. Exercise transiently increases pro-inflammatory cytokines (IL-6, IL-1β, TNF-α), facilitating crosstalk between immune and non-immune cells to initiate repair56. Beyond CRP, WBC is widely used as a surrogate marker of chronic inflammation57, with leukocytosis primarily driven by neutrophils and macrophages58.

In this analysis, long-term IPC-induced WBC change arose from a modest increase in the IPC group coupled with a slight decrease in CON. Although statistically significant, this observation should be regarded as a preliminary rather than definitive, given the high biological variability and low specificity of WBC counts, as well as the absence of concomitant changes in CRP levels or performance-related outcomes. Its long-term clinical and physiological relevance warrants further investigation.

(5) Cardiovascular and subjective responses: SBP, DBP, HR, and RPE showed no differences (p > 0.05). This indicates that IPC did not add extra cardiovascular load or alter perceived fatigue. This finding is consistent with the known safety profile of IPC59.

(6) Erythrocyte system: RBC and Hb did not change, whereas RDW significantly improved (p < 0.05). This may be related to improved endothelial function and bone marrow microenvironment, potentially reflecting enhanced erythrocyte turnover or reduced heterogeneity in erythrocyte size60. Meta-analysis results showed that the decrease in RDW in the experimental group following long-term IPC intervention was significantly greater than that in the control group (p < 0.05). As a routine erythrocyte parameter61, RDW reflects the heterogeneity of RBC volume, and its elevation typically indicates impaired erythropoiesis or the presence of systemic inflammation62,63. IPC, as a mild and repeatable conditioning stimulus46, did not induce cumulative RBC damage; rather, it upregulated the expression of genes related to nitric oxide production and oxidative stress defense64, thereby enhancing RBC membrane stability. Previous studies have also demonstrated that five consecutive days of daily IPC repetition suffice to improve RBC deformability, which has been positively correlated with exercise performance64. The systemic reduction in RDW further reflects hemorheological optimization induced by long-term IPC, including enhanced RBC deformability and improved microcirculatory perfusion. These changes augment the oxygen-carrying and unloading capacity per unit of blood, thereby establishing a superior oxygen transport foundation for endurance performance10. This positive cumulative effect suggests that low-intensity, high-frequency repeated stimulation, through a preconditioning mechanism, facilitates sustained physiological upgrades in the hematopoietic system and vascular endothelial function, rather than merely triggering transient acute stress responses.

The results of this study do not support a broad ergogenic effect of long-term IPC on athletic performance. Its effects are not a simple summation of acute IPC effects. The observed effects may be influenced by multiple factors such as intervention protocol, exercise modality, and individual adaptation. This result is inconsistent with the positive findings of some previous acute IPC studies8 but consistent with some findings of Marocolo et al.65.

Innovation

This study is the first meta-analysis focusing on the athletes’ cohort to investigate the effects of long-term IPC on athletic performance. It aims to reveal the applicability of long-term IPC in this specific group and provide insights for guiding sports training practices.

Limitations

The number of studies included in this analysis is relatively small, with only 11 eligible articles. Although we performed a systematic search across multiple databases, available studies on long-term IPC and athletic performance remain limited. One additional study was excluded because effective data could not be extracted. Importantly, the intervention duration of the included studies ranged from 1 to 8 weeks. pooling protocols of varying durations poses a conceptual challenge. From a physiological perspective, 1-week interventions may primarily affect endothelial function and inflammatory pathways, whereas 4 to 8 weeks’ protocols may induce deeper adaptations such as mitochondrial biogenesis and structural remodeling. These different durations are unlikely to be physiologically equivalent.

Ideally, subgroup analyses or meta-regression stratified by intervention duration should be conducted to explore sources of heterogeneity. However, with only 11 included studies and most pooled analyses based on 2-4 studies, such analyses were not methodologically feasible. Therefore, our definition of “long-term” as ≥7 days represents a pragmatic choice based on operational feasibility, not a claim of physiological equivalence across durations. We explicitly acknowledge this as an important limitation.

In addition, this study evaluated a large number of outcome measures, including exercise performance, aerobic endurance, anaerobic power, metabolic stress, muscle damage markers, inflammatory markers, cardiovascular responses, RPE, and erythrocyte parameters. Under these circumstances, statistically significant findings in isolated indicators could arise by chance (Type I error). Although formal correction for multiple testing is not commonly performed in meta-analyses and may be overly conservative, we acknowledge this limitation. Therefore, the isolated significant findings for PPO, WBC, and RDW should be interpreted with caution and should not be overemphasized.

Furthermore, although all included studies were randomized controlled trials, the total sample size was limited (209 athletes), and most pooled analyses were based on only 2–4 studies. Therefore, the certainty of evidence in this meta-analysis remains relatively low, and the conclusions should be regarded as exploratory rather than definitive. As more high-quality, long-term IPC intervention studies become available in the future, our conclusions may need to be revised or updated.

Conclusion

This meta-analysis evaluated the effects of long-term (≥7 days) IPC on athletic performance and physiological parameters in athletes. Eleven randomized controlled trials involving 209 athletes were included.

The results showed a statistically significant increase in PPO in a limited number of studies, along with significant changes in WBC and RDW (p < 0.05). However, no significant effects were observed for CT, VO₂ peak, MPO, FI%, BLa, CK, CRP, SBP, HR, RPE, RBC, or Hb (p > 0.05).

The performance-enhancing effects of long-term IPC in athletes appear to be limited. Although long-term IPC demonstrates potential in improving certain hematological parameters, current evidence does not robustly support its efficacy in enhancing overall athletic performance, accelerating recovery from muscle damage, or reducing perceived fatigue in athletes. The observed improvement in PPO should be interpreted with caution, as it was not consistently supported by other anaerobic indicators. Future studies should implement repeated IPC interventions across different sports to identify effective long-term training protocols.

Conflict of interests. The authors declare that there is no conflict of interest.

Authors’ contributions. YL and MF: information retrieval, overall design, and writing of the paper. JL: paper review and research guidance. QH: research guidance and revision. JG, RY, MW, JZ and XP: information retrieval, data extraction, and quality evaluation of the paper; any disagreements were resolved by MF. YL and MF contributed equally to this manuscript and are co-first authors.

Funding. This research was supported by the Fundamental Research Funds for the Central Universities (Project Title: Research on Key Technologies for Enhancing Athletic Performance; Project No.: 2025KYPT04).

Availability of data and materials. The data extracted from included studies and used for the analyses are presented in their entirety in the tables and figures of this manuscript and its supplementary appendices.

Acknowledgements. We are grateful to the authors of all studies cited in this research and to the reviewers for their valuable comments.

References

1. Su Y, LI W. Advances in research on the potential physiological mechanisms and applications of remote ischemic preconditioning in sports practice. China Sport Science and Technology 2024; 60: 31-9.

2. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986; 74: 1124-36.

3. Eisen A, Fisman EZ, Rubenfire M, et al. Ischemic preconditioning: nearly two decades of research. A Comprehensive Review. Atherosclerosis 2004; 172: 201-10.

4. Fan Z, Wu Y. Ischemic conditioning in sports training: effects, mechanisms, and considerations. Chinese Journal of Sports Medicine 2024; 43: 753-66.

5. Wang Z, Wu Y. Ischemic preconditioning improves exercise performance: methods, applications and mechanisms. Chinese Journal of Tissue Engineering Research 2023; 27: 4869-75.

6. Fan Z, Shi L, Wu Y. Effects and mechanism of remote ischemic preconditioning on enhancing exercise performance. China Sport Science and Technology 2023; 59: 15-23+32.

7. Narayanan SV, Dave KR, Perez-Pinzon MA. Ischemic preconditioning and clinical scenarios. Curr Opin Neurol 2013; 26: 1-7.

8. Salvador AF, De Aguiar RA, Lisbôa FD, Pereira KL, Cruz RS, Caputo F. Ischemic preconditioning and exercise performance: a systematic review and meta-analysis. Int J Sports Physiol Perform 2016; 11: 4-14.

9. de Groot PC, Thijssen DH, Sanchez M, Ellenkamp R, Hopman MT. Ischemic preconditioning improves maximal performance in humans. Eur J Appl Physiol 2010; 108: 141-6.

10. Marocolo M, Souza HLR, Surke P, Ferrauti A. Potential short- and long-term physiological effects of ischemic preconditioning as an ergogenic aid: revisiting foundational mechanisms and applications. Sports Med 2025; 55: 1547-57.

11. Pryds K, Rahbek Schmidt M, Bjerre M, et al. Effect of long-term remote ischemic conditioning on inflammation and cardiac remodeling. Scand Cardiovasc J 2019; 53: 183-91.

12. Yamaguchi T, Izumi Y, Nakamura Y, et al. Repeated remote ischemic conditioning attenuates left ventricular remodeling via exosome-mediated intercellular communication on chronic heart failure after myocardial infarction. Int J Cardiol 2015; 178: 239-46.

13. Liang Y, Li YP, He F, Liu XQ, Zhang JY. Long-term, regular remote ischemic preconditioning improves endothelial function in patients with coronary heart disease. Braz J Med Biol Res 2015; 48: 568-76.

14. Pryds K, Nielsen RR, Jorsal A, et al. Effect of long-term remote ischemic conditioning in patients with chronic ischemic heart failure. Basic Res Cardiol 2017; 112: 67.

15. Wax B, Kerksick CM, Jagim AR, Mayo JJ, Lyons BC, Kreider RB. Creatine for exercise and sports performance, with recovery considerations for healthy populations. Nutrients 2021; 13.

16. Llanos-Lagos C, Ramirez-Campillo R, Moran J, Sáez de Villarreal E. The effect of strength training methods on middle-distance and long-distance runners’ athletic performance: a systematic review with meta-analysis. Sports Med 2024; 54: 1801-33.

17. Shimizu M, Saxena P, Konstantinov IE, et al. Remote ischemic preconditioning decreases adhesion and selectively modifies functional responses of human neutrophils. J Surg Res 2010; 158: 155-61.

18. Kono Y, Fukuda S, Hanatani A, et al. Remote ischemic conditioning improves coronary microcirculation in healthy subjects and patients with heart failure. Drug Des Devel Ther 2014; 8: 1175-81.

19. Jones H, Hopkins N, Bailey TG, Green DJ, Cable NT, Thijssen DH. Seven-day remote ischemic preconditioning improves local and systemic endothelial function and microcirculation in healthy humans. Am J Hypertens 2014; 27: 918-25.

20. Daab W, Bouzid MA, Zghal F, et al. Ischemic preconditioning delayed neuromuscular fatigue development during a simulated soccer match. J Sci Med Sport 2025; 28: 770-7.

21. Zinner C, Born DP, Sperlich B. Ischemic preconditioning does not alter performance in multidirectional high-intensity intermittent exercise. Front Physiol 2017; 8: 1029.

22. Sabino-Carvalho JL, Obeid-Freitas T, Paula-Ribeiro M, et al. Ischemic preconditioning boosts post-exercise but not resting cardiac vagal control in endurance runners. Eur J Appl Physiol 2019; 119: 621-32.

23. Loukas I, Stergiopoulos D, Sotiridis A, Koskolou M, Geladas N. Applying ischemic preconditioning prior to endurance training improves hematological profile and performance in long-distance runners. Eur J Appl Physiol 2026.

24. Brzezińska P, Mieszkowski J, Stankiewicz B, et al. Direct effects of remote ischemic preconditioning on post-exercise-induced changes in kynurenine metabolism. Front Physiol 2024; 15: 1462289.

25. Sari MZ, Özkaya YG. Acute and chronic lower limb ischaemic preconditioning increase the sprint triathlon performance in athletes. International Journal of Sport, Exercise & Training Sciences 2025; 11: 246-55.

26. Slysz JT, Burr JF. Impact of 8 weeks of repeated ischemic preconditioning on running performance. Eur J Appl Physiol 2019; 119: 1431-7.

27. Yang W, Ou Z, Xu G, et al. Effects of 8-week ischemic preconditioning on swimming performance and power output in male 100-m freestyle swimmers: a randomized controlled trial. Eur J Appl Physiol 2026; 126: 991-1008.

28. Paradis-Deschênes P, Joanisse DR, Mauriège P, Billaut F. Ischemic preconditioning enhances aerobic adaptations to sprint-interval training in athletes without altering systemic hypoxic signaling and immune function. Front Sports Act Living 2020; 2: 41.

29. Bouffard S, Paradis-Deschênes P, Billaut F. Neuromuscular adjustments following sprint training with ischemic preconditioning in endurance athletes: preliminary data. Sports (Basel) 2021; 9.

30. Shannon ES, Carter SE. The effect of a 2-week ischaemic preconditioning intervention on anaerobic performance in male academy football players: a randomized, single-blinded, SHAM-Controlled study. Res Sports Med 2024; 32: 939-55.

31. Lindsay A, Petersen C, Ferguson H, Blackwell G, Rickerby S. Lack of a dose response from 7 days of ischemic preconditioning in moderately trained cyclists. Sports Med Int Open 2018; 2: E91-e7.

32. Mieszkowski J, Stankiewicz BE, Kochanowicz A, et al. Remote ischemic preconditioning reduces marathon-induced oxidative stress and decreases liver and heart injury markers in the serum. Front Physiol 2021; 12: 731889.

33. Trybulski R, Clemente FM, Ryszkiel I, et al. Effect of ischemic preconditioning on microvascular post-occlusive hyperemic reactions and quadriceps morphology in MMA: a randomized clinical trial. Eur J Appl Physiology 2025; 126: 479-92.

34. Liem DA, Verdouw PD, Ploeg H, Kazim S, Duncker DJ. Sites of action of adenosine in interorgan preconditioning of the heart. Am J Physiol Heart Circ Physiol 2002; 283: H29-37.

35. Takaoka A, Nakae I, Mitsunami K, et al. Renal ischemia/reperfusion remotely improves myocardial energy metabolism during myocardial ischemia via adenosine receptors in rabbits: effects of “remote preconditioning”. J Am Coll Cardiol 1999; 33: 556-64.

36. Wolfrum S, Schneider K, Heidbreder M, Nienstedt J, Dominiak P, Dendorfer A. Remote preconditioning protects the heart by activating myocardial PKCepsilon-isoform. Cardiovasc Res 2002; 55: 583-9.

37. Wong GT, Lu Y, Mei B, Xia Z, Irwin MG. Cardioprotection from remote preconditioning involves spinal opioid receptor activation. Life Sci 2012; 91: 860-5.

38. Hausenloy DJ, Yellon DM. Cell membrane repair as a mechanism for ischemic preconditioning? Circulation 2010; 121: 2547-9.

39. Wu X, Liu L, Zheng Q, et al. Dihydrotanshinone I preconditions myocardium against ischemic injury via PKM2 glutathionylation sensitive to ROS. Acta Pharm Sin B 2023; 13: 113-27.

40. Schwanke U, Konietzka I, Duschin A, Li X, Schulz R, Heusch G. No ischemic preconditioning in heterozygous connexin43-deficient mice. Am J Physiol Heart Circ Physiol 2002; 283: H1740-2.

41. Ishida T, Yarimizu K, Gute DC, Korthuis RJ. Mechanisms of ischemic preconditioning. Shock 1997; 8: 86-94.

42. Costa JF, Fontes-Carvalho R, Leite-Moreira AF. Myocardial remote ischemic preconditioning: from pathophysiology to clinical application. Rev Port Cardiol 2013; 32: 893-904.

43. Cheung MM, Kharbanda RK, Konstantinov IE, et al. Randomized controlled trial of the effects of remote ischemic preconditioning on children undergoing cardiac surgery: first clinical application in humans. J Am Coll Cardiol 2006; 47: 2277-82.

44. Moscarelli M, Angelini GD, Emanueli C, et al. Remote ischemic preconditioning in isolated valve intervention. A pooled meta-analysis. Int J Cardiol 2021; 324: 146-51.

45. Gorjipour F, Saeedzadeh T, Toloueitabar Y, et al. Remote ischemic preconditioning effects on inflammatory markers and myocardial protection in coronary artery bypass graft surgery. Perfusion 2022; 37: 56-61.

46. Anttila V, Haapanen H, Yannopoulos F, Herajärvi J, Anttila T, Juvonen T. Review of remote ischemic preconditioning: from laboratory studies to clinical trials. Scand Cardiovasc J 2016; 50: 355-61.

47. Bailey TG, Jones H, Gregson W, Atkinson G, Cable NT, Thijssen DH. Effect of ischemic preconditioning on lactate accumulation and running performance. Med Sci Sports Exerc 2012; 44: 2084-9.

48. Stöggl T, Sperlich B. Polarized training has greater impact on key endurance variables than threshold, high intensity, or high volume training. Front Physiol 2014; 5: 33.

49. Cheng CF, Kuo YH, Hsu WC, Chen C, Pan CH. Local and remote ischemic preconditioning improves sprint interval exercise performance in team sport athletes. Int J Environ Res Public Health 2021; 18.

50. Cruz RS, de Aguiar RA, Turnes T, Pereira KL, Caputo F. Effects of ischemic preconditioning on maximal constant-load cycling performance. J Appl Physiol (1985) 2015; 119: 961-7.

51. Wu Y, Fan Z, Gao Z, Wang Z. Impact of ischemic conditioning on fatigue recovery following high-intensity complex training. Int J Sports Physiol Perform 2025; 20: 1378-85.

52. Carvalho L, Barroso R. Ischemic preconditioning improves strength endurance performance. J Strength Cond Res 2019; 33: 3332-7.

53. Maia F, Nakamura FY, Sarmento H, Marcelino R, Ribeiro J. Effects of lower-limb intermittent pneumatic compression on sports recovery: a systematic review and meta-analysis. Biol Sport 2024; 41: 263-75.

54. Xu Y, Su S, McCall WV, Wang X. Blunted rest-activity rhythm is associated with increased white blood-cell-based inflammatory markers in adults: an analysis from NHANES 2011-2014. Chronobiol Int 2022; 39: 895-902.

55. Moro T, Tinsley G, Longo G, et al. Time-restricted eating effects on performance, immune function, and body composition in elite cyclists: a randomized controlled trial. J Int Soc Sports Nutr 2020; 17: 65.

56. Allen J, Sun Y, Woods JA. Exercise and the regulation of inflammatory responses. Prog Mol Biol Transl Sci 2015; 135: 337-54.

57. You Y, Chen Y, Fang W, et al. The association between sedentary behavior, exercise, and sleep disturbance: A mediation analysis of inflammatory biomarkers. Front Immunol 2022; 13: 1080782.

58. Connolly PH, Caiozzo VJ, Zaldivar F, et al. Effects of exercise on gene expression in human peripheral blood mononuclear cells. J Appl Physiol (1985) 2004; 97: 1461-9.

59. Huang H, Ruan Y, Li C, et al. Hypoxia microenvironment preconditioning attenuated myocardial ischemia-reperfusion injury via stc1-mediating cardiomyocyte self-protection and neutrophil polarization. Adv Sci (Weinh) 2025; 12: e2411880.

60. Caimi G, Carlisi M, Presti RL. Red blood cell distribution width, erythrocyte indices, and elongation index at baseline in a group of trained subjects. J Clin Med 2023; 13.

61. Vayá A, Sarnago A, Fuster O, Alis R, Romagnoli M. Influence of inflammatory and lipidic parameters on red blood cell distribution width in a healthy population. Clin Hemorheol Microcirc 2015; 59: 379-85.

62. Wei S, Ma Y, Zhang N, et al. Hemoglobin-to-red blood cell distribution width ratio and risk of fragility fracture: a 16-year prospective cohort study. J Formos Med Assoc 2025.

63. Vayá A, Alis R, Suescún M, et al. Association of erythrocyte deformability with red blood cell distribution width in metabolic diseases and thalassemia trait. Clin Hemorheol Microcirc 2015; 61: 407-15.

64. Grau M, Seeger B, Mozigemba L, et al. Effects of recurring ipc vs. Ripc maneuvers on exercise performance, pulse wave velocity, and red blood cell deformability: special consideration of reflow varieties. Biology (Basel) 2022; 11.

65. Marocolo M, da Mota GR, Simim MA, Appell Coriolano HJ. Myths and facts about the effects of ischemic preconditioning on performance. Int J Sports Med 2016; 37: 87-96.